IL stock · Healthcare sector · Drug Manufacturers—Specialty & Generic
T
Teva Pharmaceutical Industries Limited
TEVA
NYSE7.45
USD
+0.12
(+1.64%)
Market Closed
-4.89P/E
3Forward P/E
-0.20P/E to S&P500
8.491BMarket CAP
- -Div Yield
Upcoming Earnings
- -
Shares Short
5/15/23
13.97M
Short % of Float
- -
Short % of Shares Outs.
1.25%
% Held by Insiders
- -
% Held by Institutions
51.06%
Beta
1.19
PEG Ratio
2.02
52w. high/low
11.45/6.78
Avg. Daily Volume
11.72M
Return %
Stock
S&P 500
1 year
(16.91)
2.12
3 years
(40.24)
40.04
5 years
(65.84)
54.55
Scale: |
High
Low
50.00
35.89
56.88
41.05
64.95
46.99
57.08
35.00
46.65
36.63
41.74
36.26
58.95
39.64
72.31
54.17
65.92
34.57
38.31
10.85
25.96
14.59
20.21
6.07
13.76
6.25
13.30
7.73
11.34
6.78
11.45
7.25
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
12.25
14.21
15.94
17.99
20.58
23.30
23.93
23.77
22.98
22.94
22.03
18.47
15.48
15.21
14.41
13.45
13.43
Earnings per share
2.54
0.81
2.29
3.72
3.10
2.25
1.49
3.58
1.86
0.34
(16.01)
(2.11)
(0.92)
(3.64)
0.38
(2.12)
(1.49)
FCF per share
1.65
3.27
3.04
3.82
3.46
3.98
2.60
4.92
5.58
4.53
2.59
1.76
0.20
0.58
0.21
0.94
0.87
Dividends per share
0.39
0.50
0.61
0.75
0.90
0.98
1.28
1.36
1.35
1.63
1.14
0.02
0.05
- -
- -
- -
- -
CAPEX per share
0.71
0.87
0.82
0.79
1.18
1.27
1.21
1.09
0.90
0.94
0.86
0.64
0.48
0.53
0.51
0.49
0.48
Book Value per sh.
17.87
20.90
22.04
24.49
24.94
26.11
26.58
27.33
34.82
34.91
17.09
14.40
12.81
9.16
9.33
7.83
7.72
Comm.Shares outs.
768
780
872
896
890
872
849
853
855
955
1,016
1,021
1,091
1,095
1,102
1,110
1,112
Avg. annual P/E ratio
15.9
55.4
21.1
14.8
14.7
18.5
26.1
14.4
33.1
148.0
(1.6)
(9.9)
(12.6)
(2.9)
26.7
(4.1)
(4.9)
P/E to S&P500
0.9
2.6
0.3
0.7
0.9
1.2
1.5
0.8
1.7
6.7
(0.1)
(0.4)
(0.5)
(0.1)
0.9
(0.2)
(0.2)
Avg. annual div. yield
1.0%
1.1%
1.3%
1.4%
2.0%
2.3%
3.3%
2.6%
2.2%
3.2%
4.3%
0.1%
0.4%
- -
- -
- -
- -
Revenue (m)
9,408
11,085
13,899
16,121
18,312
20,317
20,314
20,272
19,652
21,903
22,385
18,854
16,887
16,658
15,879
14,925
14,926
Operating margin
25.5%
10.3%
17.3%
24.0%
17.0%
10.9%
8.1%
19.5%
17.1%
9.8%
(78.1)%
(8.7)%
(2.6)%
(21.4)%
10.8%
(14.1)%
14.1%
Depreciation (m)
521
493
908
977
1,069
1,708
1,642
1,508
1,308
1,524
2,112
1,842
1,722
1,557
1,330
1,308
985
Net profit (m)
1,952
635
2,000
3,331
2,759
1,963
1,269
3,055
1,588
329
(16,265)
(2,150)
(999)
(3,990)
417
(2,353)
(1,663)
Income tax rate
16.9%
22.4%
7.5%
7.8%
4.3%
(7.5)%
(3.4)%
16.2%
27.0%
63.2%
10.5%
7.5%
22.0%
3.8%
32.1%
20.8%
37.1%
Net profit margin
20.7%
5.7%
14.4%
20.7%
15.1%
9.7%
6.2%
15.1%
8.1%
1.5%
(72.7)%
(11.4)%
(5.9)%
(24.0)%
2.6%
(15.8)%
(10.8)%
Working capital (m)
4,488
2,945
4,539
2,348
606
3,467
1,755
2,107
5,393
(1,558)
(2,539)
(528)
(210)
(159)
1,546
582
1,090
Long-term debt (m)
3,347
5,537
4,311
4,110
10,236
11,712
10,387
8,566
8,383
32,524
28,829
26,700
24,997
23,210
22,033
19,452
20,013
Equity (m)
13,724
16,300
19,222
21,947
22,195
22,768
22,565
23,313
29,769
33,337
17,359
14,707
13,972
10,026
10,278
8,691
8,612
ROIC
10.8%
3.6%
8.5%
12.5%
8.0%
6.2%
4.5%
9.7%
4.4%
0.7%
(30.2)%
(2.9)%
(0.7)%
(8.4)%
2.9%
(7.3)%
4.0%
Return on capital
10.0%
3.5%
7.1%
10.1%
6.1%
4.3%
3.2%
8.5%
4.6%
1.5%
(25.0)%
(2.4)%
(0.7)%
(6.4)%
3.3%
(6.8)%
4.9%
Return on equity
14.2%
3.9%
10.4%
15.2%
12.4%
8.6%
5.6%
13.1%
5.3%
1.0%
(93.7)%
(14.6)%
(7.2)%
(39.8)%
4.1%
(27.1)%
(19.3)%
Plowback ratio
84.7%
38.9%
73.7%
80.0%
71.1%
55.2%
13.1%
62.0%
27.7%
(401.0)%
107.1%
100.9%
105.2%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
18.8%
15.2%
19.9%
22.4%
55.1%
58.1%
71.9%
39.4%
(35.6)%
28.4%
- -
- -
- -
- -
- -
- -
- -
Capital Structure
10 May · 2023 | Q1
All numbers in millions
Total liabilities
$ 34,844
Total assets
$ 43,456
Long-term debt
$ 20,013
Cash and equiv.
$ 2,143
Goodwill
$ 17,799
Retained earnings
$ (13,086)
Common stock
1,115
Enterprise Value
$ 26,361
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
2,177
2,165
2,801
Receivables
4,581
4,529
3,696
Inventory
4,403
3,818
3,833
Other
1,844
2,049
2,345
Current assets
13,005
12,573
12,051
Acc. Payable
1,756
1,686
1,887
Debt due
3,188
1,426
2,109
Other
8,220
7,915
7,473
Current liabilities
13,164
11,027
11,469
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(6.01)%
(5.62)%
(3.10)%
Cash flow
341.53%
94.26%
44.52%
Earnings
(664.27)%
(132.21)%
(627.33)%
Dividends
- -
- -
- -
Book value
(15.44)%
(11.54)%
(7.38)%
Insider Trading
Type
Shares
Date
Stark David Matthew
Sale
16,491
03/06/23
Stark David Matthew
Sale
49,475
03/07/23
Drape Eric
Sale
1,566
03/06/23
Drape Eric
Sale
4,699
03/07/23
Dethlefs Sven
Sale
19,355
03/06/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
3,982
3,910
3,886
4,100
15,878
2022
3,661
3,786
3,595
3,884
14,926
2023
3,661
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.07
0.19
0.26
(0.14)
0.39
2022
(0.88)
(0.23)
0.05
(1.13)
(2.19)
2023
(0.18)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
CEO:
Mr. Richard Francis
Full-time employees:
34,004
City:
Tel Aviv
Address:
124 Dvora Hanevi’a Street
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Recent News
· 21 Nov, 2022 · The Wall Street Journal
· 14 Oct, 2022 · The Wall Street Journal
· 18 Apr, 2022 · The Wall Street Journal
· 31 Dec, 2021 · The Wall Street Journal